search
Back to results

Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB

Primary Purpose

Chronic Hepatitis b

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Vitamin D
Sponsored by
Third Affiliated Hospital, Sun Yat-Sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Hepatitis b focused on measuring hepatitis B, Vitamin D, Interferon

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 1.According with the diagnosis of chronic hepatitis B in the guideline of China in 2015 2.18-60 years old 3.More than 1 year history of nucleot(s)ide analogues therapy with HBsAg ≤1500 IU/ml, negative HBeAg and HBV DNA<100 IU/ml 4.No contraindications of interferon Exclusion Criteria: Allergy to interferon Alanine transaminase >10 times of upper limit of normal(ULN) or total bilirubin >2 times of ULN existing or previous decompensated liver cirrhosis White blood cells or Platelet below the lower limit of normal existing severe organ injury combined with autoimmune diseases, psychiatric diseases, diabetes or thyroidism confirmed or suspected malignant tumors before or after transplantation using immunosuppressor pregnant or having a planned parenthood in 2 years alcohol or drug addicted infected by HIV any conditions that is unsuitable to interferon therapy according to the doctors' judgement

Sites / Locations

  • Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

treatment group

control group

Arm Description

pegylated interferon 180ug/week and oral vitamin D3 800IU/day for no longer than 48 weeks

pegylated interferon 180ug/week for no longer than 48 weeks

Outcomes

Primary Outcome Measures

hepatitis B surface antigen
hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml.

Secondary Outcome Measures

hepatitis B surface antibody
hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml

Full Information

First Posted
February 22, 2023
Last Updated
March 2, 2023
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT05753280
Brief Title
Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB
Official Title
Effect of Serum Vitamin D Level and Vitamin D Receptor on the Efficacy of Pegylated Interferon in Patients With Chronic Hepatitis B With Low Level HBsAg Treated by Nucleos(t)Ide Analogues
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
December 1, 2018 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Third Affiliated Hospital, Sun Yat-Sen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In recent years, vitamin D (VD) has received much attention in the fields of host immune regulation, inflammation, fibrosis, cell proliferation and differentiation and tumor. VD works by binding to the vitamin D receptor (VDR). VDR is mainly distributed in giant cells, dendritic cells, T cells and lymphocytes. Four SNPs of VDRS have been most studied: TaqI (rs731236), FokI (rs10735810), ApaI (rs7975232), and BsmI (rs1544410). At present, more and more patients have been treated with oral nucleotide/nucleoside analogues (NAs) with direct antiviral drugs in China, and a large part of them show low expression of HBsAg. Clinical cure can be pursued for these patients, that is, HBsAg turns negative. A number of studies have been carried out at home and abroad. In this study, We will recruit CHB patients with low HBsAg levels. They all will receive pegylated interferon treatment and were randomly assigned to a vitamin D treatment or a control group. A final assessment will be made to determine whether vitamin D levels would affect the clearance rate of HBsAg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis b
Keywords
hepatitis B, Vitamin D, Interferon

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
treatment group
Arm Type
Experimental
Arm Description
pegylated interferon 180ug/week and oral vitamin D3 800IU/day for no longer than 48 weeks
Arm Title
control group
Arm Type
No Intervention
Arm Description
pegylated interferon 180ug/week for no longer than 48 weeks
Intervention Type
Drug
Intervention Name(s)
Vitamin D
Intervention Description
Patients take 800 mg vitamin D capsules daily during the whole treatment period
Primary Outcome Measure Information:
Title
hepatitis B surface antigen
Description
hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml.
Time Frame
up to 48 weeks
Secondary Outcome Measure Information:
Title
hepatitis B surface antibody
Description
hepatitis B surface antigen should be tested by the reagents from Roche or Abbott, which is expressed by using IU/ml
Time Frame
every 12 weeks for up to 48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1.According with the diagnosis of chronic hepatitis B in the guideline of China in 2015 2.18-60 years old 3.More than 1 year history of nucleot(s)ide analogues therapy with HBsAg ≤1500 IU/ml, negative HBeAg and HBV DNA<100 IU/ml 4.No contraindications of interferon Exclusion Criteria: Allergy to interferon Alanine transaminase >10 times of upper limit of normal(ULN) or total bilirubin >2 times of ULN existing or previous decompensated liver cirrhosis White blood cells or Platelet below the lower limit of normal existing severe organ injury combined with autoimmune diseases, psychiatric diseases, diabetes or thyroidism confirmed or suspected malignant tumors before or after transplantation using immunosuppressor pregnant or having a planned parenthood in 2 years alcohol or drug addicted infected by HIV any conditions that is unsuitable to interferon therapy according to the doctors' judgement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhiliang Gao, Doctor
Organizational Affiliation
Third Affiliated Hospital, Sun Yat-Sen University
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510630
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB

We'll reach out to this number within 24 hrs